Myriad Pharmaceuticals Presents Data From Nampt Inhibitor Program at AACR 101st Annual Meeting
April 20, 2010 14:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, April 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preclinical data characterizing MPI-0486348, the lead compound in the...
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
April 19, 2010 09:05 ET
|
Myrexis, Inc.
SALT LAKE CITY, April 19, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with...
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
April 12, 2010 09:32 ET
|
Myrexis, Inc.
SALT LAKE CITY, April 12, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc (Nasdaq:MYRX) today announced that it has received a notice from Javelin Pharmaceuticals, Inc. (NYSE Amex:JAV) of its...
Myriad Pharmaceuticals, Inc. Sets Date for Special Stockholder Meeting to Approve Merger with Javelin Pharmaceuticals, Inc.
March 15, 2010 09:15 ET
|
Myrexis, Inc.
SALT LAKE CITY, March 15, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX), announced today that a registration statement on Form S-4 relating to the proposed merger with Javelin...
Myriad Pharmaceuticals Reports Second Quarter FY' 2010 Financial Results
February 16, 2010 16:15 ET
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its second fiscal quarter ended December 31, 2009.
"We are pleased...
Myriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8th
February 03, 2010 09:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 3, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today...
FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)
February 02, 2010 09:09 ET
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’...
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
December 18, 2009 08:15 ET
|
Myrexis, Inc.
Creates Pipeline With Potential Near-Term Product Launch of
Dyloject(TM) and Portfolio of Early-, Mid- and Late-Stage
Drug Candidates in Cancer, HIV and Pain
...
Myriad Pharmaceuticals Initiates Phase 2b Study of MPC-4326 in a Genetically-Identified Responder Population
December 01, 2009 08:00 ET
|
Myrexis, Inc.
SALT LAKE CITY, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the initiation of a Phase 2b study of MPC-4326, a first-in-class, small molecule inhibitor of...
Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
November 23, 2009 21:51 ET
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) announced today that Adrian Hobden, President and CEO, is scheduled to present an overview of the Company at...